You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Clinical Characteristics, Baseline Hemodynamics, and Exercise Capacity of the Studied Patient Sample

Used with permission from: Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.

Table 2.  

Acute NO/Epoprostenol Responders Group (n = 70) Long-term CCB Responders Group (n = 38) CCB Failure Group (n = 32) P*
Drug tested (NO:epoprostenol) (n) 57:13 33:5 24:8 .2
Mean PAP reached during acute vasodilator testing (mm Hg) 38 ± 11 (18-65) 33 ± 8 (18-50) 46 ± 10 (18-65) < .001
Fall in mean PAP during acute vasodilator testing (mm Hg) 19 ± 7 (10-36) 21 ± 7 (10 - 36) 16 ± 6 (10 - 33) .006
Percent fall in mean PAP 33 ± 11 (20-59) 39 ± 11 (20 - 59) 26 ± 7 (20 - 49) < .001
PVR reached during acute vasodilator testing (WU) 6.6 ± 3.4 (1.1 - 17.4) 5.2 ± 2.7 (1.1 - 13.1) 8.6 ± 3.3 (1.1 - 17.4) < .001
Fall in PVR during acute vasodilator testing (WU) 5.6 ± 3.3 (1.6 - 16.7) 5.1 ± 3.1 (1.7 - 15.4) 6.2 ± 3.4 (1.6 -16.7) .16
Percent fall in PVR 45 ± 15 (24-77) 50 ± 15 (24 - 77) 40 ± 13 (26 - 75) .007

Hemodynamic Values Reached During Vasodilator Testing in Acute Responders

Values are mean ± SD (range).
*Comparison between long-term CCB responders and CCB failure groups (unpaired Student t or x 2 test, as appropriate.
CCB = calcium channel blockers; CO = cardiac output; NO = nitric oxide; PAP = pulmonary arterial pressure; PVR = pulmonary vascular resistance; WU = Wood units
Used with permission from: Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.

Table 2.  

Acute NO/Epoprostenol Responders Group (n = 70) Long-term CCB Responders Group (n = 38) CCB Failure Group (n = 32) P*
Drug tested (NO:epoprostenol) (n) 57:13 33:5 24:8 .2
Mean PAP reached during acute vasodilator testing (mm Hg) 38 ± 11 (18-65) 33 ± 8 (18-50) 46 ± 10 (18-65) < .001
Fall in mean PAP during acute vasodilator testing (mm Hg) 19 ± 7 (10-36) 21 ± 7 (10 - 36) 16 ± 6 (10 - 33) .006
Percent fall in mean PAP 33 ± 11 (20-59) 39 ± 11 (20 - 59) 26 ± 7 (20 - 49) < .001
PVR reached during acute vasodilator testing (WU) 6.6 ± 3.4 (1.1 - 17.4) 5.2 ± 2.7 (1.1 - 13.1) 8.6 ± 3.3 (1.1 - 17.4) < .001
Fall in PVR during acute vasodilator testing (WU) 5.6 ± 3.3 (1.6 - 16.7) 5.1 ± 3.1 (1.7 - 15.4) 6.2 ± 3.4 (1.6 -16.7) .16
Percent fall in PVR 45 ± 15 (24-77) 50 ± 15 (24 - 77) 40 ± 13 (26 - 75) .007

Hemodynamic Values Reached During Vasodilator Testing in Acute Responders

Values are mean ± SD (range).
*Comparison between long-term CCB responders and CCB failure groups (unpaired Student t or x 2 test, as appropriate.
CCB = calcium channel blockers; CO = cardiac output; NO = nitric oxide; PAP = pulmonary arterial pressure; PVR = pulmonary vascular resistance; WU = Wood units
Used with permission from: Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105-3111.

Table 3.  

Used with permission from: Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208.

The Role of Calcium Channel Blockers in Pulmonary Arterial Hypertension

Authors: Ivan Robbins, MDFaculty and Disclosures

processing....

Introduction

Calcium channel blockers (CCBs) have been used in the treatment of pulmonary arterial hypertension (PAH) for over 25 years. Despite this, they have never been evaluated in a randomized trial in patients with PAH. In addition, although there are presently 5 drugs approved for the treatment of PAH, including 2 oral medications, many clinicians still are familiar only with CCBs as a therapeutic option for patients with PAH. Although some patients exhibit significant improvement after treatment with CCBs, these drugs only benefit a small minority of patients with PAH and have been studied almost exclusively in patients with idiopathic PAH (IPAH).